MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer

被引:21
作者
Tao, Zuo [1 ]
Suo, Huandan [1 ]
Zhang, Lei [1 ]
Jin, Zining [1 ]
Wang, Zhen [1 ]
Wang, Danyu [1 ]
Wu, Ming [1 ]
Peng, Nanxi [1 ]
Zhao, Yujie [1 ]
Chen, Bo [1 ]
机构
[1] China Med Univ, Hosp 1, Dept Breast Surg, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2020年 / 13卷
关键词
cancer genome map; breast cancer; MRPL13; clinical significance; MATRIX METALLOPROTEINASES; ANGIOGENESIS; PATHWAY; GROWTH; VEGF; MITOCHONDRIA; ASSOCIATION; INHIBITION; MECHANISMS; PROTEINS;
D O I
10.2147/OTT.S263998
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: To study the expression of MRPL13 in breast cancer tissues using TCGA database, analyze the correlation between the expression and clinicopathological characteristics of patients, and explore the role of MRPL13 in the development of breast cancer (BC). Methods: The BC mRNA data and clinical information were downloaded from TCGA database. The correlation between MRPL13 expression and clinicopathological parameters was analyzed. Cox regression multivariate analysis was used to explore the factors affecting the prognosis of BC patients. The UALCAN database was used to analyze the expression level of MRPL13 in BC and its relationship with clinical pathological factors. The GSEA method was used to predict the possible regulatory pathways of MRPL13. Immune responses of MRPL13 expression were analyzed using TISIDB and CIBERSORT. Additionally, GEPIA, K-M survival analysis and data from the HPA were used to validate the outcomes. Results: The expression of MRPL13 in BC tissues was significantly higher than normal counterparts, patients with low MRPL13 expression had a better survival prognosis, also indicated an independent prognostic factor. GSEA analysis showed that the regulation of cell migration, positive regulation of endothelial cell migration, and Notch signaling pathway were enriched in tissues with low expression of MRPL13. Additionally, depleting MRPL13 expression inhibited invasion in MCF-10A and MCF-7 cells. Furthermore, PCR showed that MRPL13 affected VEGFA and MMP gene expression. CIBERSORT analysis revealed that the amount of NK cells decreased when MRPL13 expression was high. Conclusion: The expression of MRPL13 mRNA is upregulated in BC tissues, and the expression level of MRPL13 is significantly related to the clinicopathological factors of patients. High MRPL13 expression is a poor prognostic factor for BC, and it can be used as a molecular marker for prognosis judgment and as a potential therapeutic target.
引用
收藏
页码:12255 / 12268
页数:14
相关论文
共 51 条
[2]   Hhip regulates tumor-stroma-mediated upregulation of tumor angiogenesis [J].
Agrawal, Vijayendra ;
Kim, Dong Young ;
Kwon, Young-Guen .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2017, 49 :e289-e289
[3]   Bevacizumab Treatment for Advanced Breast Cancer [J].
Alvarez, Ricardo H. ;
Guarneri, Valentina ;
Icli, Fikri ;
Johnston, Stephen ;
Khayat, David ;
Loibl, Sibylle ;
Martin, Miguel ;
Zielinski, Christoph ;
Conte, PierFranco ;
Hortobagyi, Gabriel N. .
ONCOLOGIST, 2011, 16 (12) :1684-1697
[4]   Breast Cancer Metastasis: Are Cytokines Important Players During Its Development and Progression? [J].
Angelica Mendez-Garcia, Lucia ;
Elizabeth Nava-Castro, Karen ;
de Lourdes Ochoa-Mercado, Tania ;
Isabel Palacios-Arreola, Margarita ;
Alejandra Ruiz-Manzano, Rocio ;
Segovia-Mendoza, Mariana ;
Solleiro-Villavicencio, Helena ;
Cazarez-Martinez, Cinthia ;
Morales-Montor, Jorge .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (01) :39-55
[5]   Resistance to Checkpoint Inhibition in Cancer Immunotherapy [J].
Barrueto, Luisa ;
Caminero, Francheska ;
Cash, Lindsay ;
Makris, Courtney ;
Lamichhane, Purushottam ;
Deshmukh, Rahul R. .
TRANSLATIONAL ONCOLOGY, 2020, 13 (03)
[6]   The Contribution of Angiogenesis to the Process of Metastasis [J].
Bielenberg, Diane R. ;
Zetter, Bruce R. .
CANCER JOURNAL, 2015, 21 (04) :267-273
[7]  
Chen Ji-Shan, 2007, Ai Zheng, V26, P972
[8]   Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges [J].
Fukurnura, Dal ;
Kloepper, Jonas ;
Amoozgar, Zohreh ;
Duda, Dan G. ;
Jain, Rakesh K. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) :325-340
[9]  
Gabriel Kipros, 2007, V390, P99
[10]   NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES [J].
Goel, Shom ;
Duda, Dan G. ;
Xu, Lei ;
Munn, Lance L. ;
Boucher, Yves ;
Fukumura, Dai ;
Jain, Rakesh K. .
PHYSIOLOGICAL REVIEWS, 2011, 91 (03) :1071-1121